Table 2 Examples of completed clinical trials related to cancer [77]
Tested compound | Condition | Clinical Trial number | Dosage | Objective | Outcomes |
|---|---|---|---|---|---|
I3C | Cancer | Clinical Trial-Phase 1- NCT00100958 | --- | To study the side effects and best dose of I3C and to see how well it works compared to a placebo in preventing cancer in healthy participants. | No study results have been posted. |
I3C | Breast Cancer | Clinical Trial-Phase 1- NCT00033345 | 400 mg daily for 4 weeks, followed by a 4-week period of 800 mg daily | To study the effectiveness of I3C in preventing breast cancer in nonsmoking women at high risk for breast cancer. | No study results have been posted. |
DIM Supplement | Breast Cancer | Clinical Trial-Phase 3- NCT02525159 | 75 mg for 30 days | To evaluate the effectiveness of supplementation with DIM to increase the urinary ratio of estrogen metabolites 2 hydroxyestrone:16 alpha-hydroxyestrone in premenopausal women at risk of breast cancer. | No study results have been posted. |
Microencapsulated DIM (BioResponse-DIM) | Prostate Cancer | Clinical Trial-Phase 2- NCT00888654 | 225 mg twice daily for 14–72 days | To study how well DIM works in treating patients with stage I or stage II prostate cancer undergoing radical prostatectomy. | -A mean level of 14.2 ng/g of DIM was found in prostate tissue after treatment. -The serum levels of PSA, testosterone, and DIM pre- and post-treatment were in ng/ml 6.4 and 5.8, 301 and 388 and 0.0 and 7.5, respectively. -The levels of androgen receptor in prostate tissue (units: intensity x % cells stained) were 278 in pre-treatment and 245 and post-treatment. -Two people out of 41 enrolled, presented headache, reported as a severe adverse event. |
Microencapsulated DIM (BioResponse-DIM) | Cervical Dysplasia | Clinical Trial-Phase 3- NCT00212381 | 2 mg/kg/day | To determine if oral DIM, is associated with the regression of cervical dysplasia in otherwise healthy women. | No study results have been posted. |
Brassica vegetables | Prostate Cancer | Clinical Trial - NCT00607932 | At least 2 servings (½ cup/serving) daily for 6 months | To study the side effects and how well Brassica vegetable work compared with I3C in treating patients with PSA recurrence after surgery for prostate cancer. | No study results have been posted. |